LaePharma and Qilu Pharma Accelerate Commercialization of Breakthrough Breast Cancer Drug LAE002 (Afuresertib) Through Exclusive Licensing Agreement in China

　　【Pharmaceutical Network Industry DynamicsOn November 12, 2025,重磅消息 rocked the biopharmaceutical field: Laekna Therapeutics and Qilu Pharmaceutical Co., Ltd. signed an exclusive licensing agreement for the Chinese market. The two parties will work together to accelerate the commercialization process of the breast cancer candidate drug LAE002 (afuresertib). This collaboration not only provides substantial financial support for Laekna Therapeutics but also holds promise to bring a new treatment option to breast cancer patients in China.
 

The core terms of this cooperation agreement highlight the sincerity of both parties and their confidence in LAE002. According to the agreement, before the first indication receives new drug application approval in China, Laekna Therapeutics will receive non-refundable upfront payments and clinical development milestone payments totaling up to 530 million yuan. Including subsequent commercial milestones, the total amount of upfront and milestone payments that Laekna Therapeutics can receive may reach up to 2.045 billion yuan. More importantly, after the drug is marketed, Laekna Therapeutics will also receive tiered sales royalties based on net sales in the Chinese region, with royalty rates ranging from over ten percentage points to over twenty percentage points. This incentive mechanism will continue to drive the company's investment in innovative drug research and development.
 

The prominent clinical value of LAE002, a candidate new drug, lies behind the substantial financial support. As a potent AKT inhibitor, LAE002 can simultaneously suppress three subtypes: AKT1, AKT2, and AKT3. This comprehensive inhibitory capability gives it a unique advantage in anti-tumor therapy. The AKT signaling pathway plays a crucial role in cell proliferation, survival, and metabolic regulation, and its abnormal activation is closely related to the development and progression of various cancers, especially in the field of breast cancer, where mutations in this pathway often lead to increased tumor drug resistance, posing significant challenges for clinical treatment. The successful development of LAE002 provides a new breakthrough for solving this problem.
 

Notably, LAE002 is one of only two AKT inhibitors globally in late-stage clinical development targeting breast cancer and prostate cancer, combining both rarity and innovation. In the field of breast cancer treatment, HR+/HER2- subtype patients account for a significant proportion, with some developing resistance to traditional endocrine therapies, leaving clinical needs largely unmet. The Phase III clinical trial (AFFIRM-205) of LAE002 for this subtype of breast cancer is proceeding as planned. Laekna Therapeutics will be responsible for completing this pivotal trial, aiming to finish patient enrollment by the fourth quarter of 2025, with plans to submit a new drug application to China's National Medical Products Administration Center for Drug Evaluation in 2026. This clear timeline has raised market expectations for the launch of this novel drug.
 

This collaboration between Laekna Therapeutics and Qilu Pharmaceutical is a typical example of complementary strengths between an innovative pharmaceutical company and a leading pharmaceutical enterprise. Laekna Therapeutics has deep technical expertise and clinical development experience in the field of innovative drug research and development, while Qilu Pharmaceutical, as one of the largest pharmaceutical companies in China, possesses strong capabilities in drug production, channel distribution, and market promotion. By joining hands, the two companies can achieve seamless integration of "R&D + commercialization," effectively shortening the timeline for LAE002 to progress from clinical trials to benefiting patients, maximizing the clinical value of the innovative drug.
 

From the perspective of industry development, this collaboration also provides valuable insights for the construction of an innovative ecosystem in China's biopharmaceuticals industry. In recent years, there has been a surge in enthusiasm for the development of innovative drugs in China, but many biotech companies face challenges such as significant financial pressure in the late clinical stages and insufficient commercialization capabilities. The partnership model between Laekna Therapeutics and Qilu Pharmaceutical, through an exclusive licensing agreement, optimizes the allocation of R&D resources and commercialization resources. It not only secures returns for the R&D enterprises but also accelerates the transformation of innovative achievements by leveraging the channel advantages of leading companies, offering a replicable template for similar collaborations within the industry.
 

For the vast number of breast cancer patients, the accelerated commercialization of LAE002 is undoubtedly a significant positive development. With the smooth progress of clinical trials and the speeding up of the market entry process, this innovative drug is expected to be put into clinical use in the near future, bringing new treatment hope to patients with drug resistance and further enhancing the overall level of breast cancer treatment in China.
 

Disclaimer: This article is organized by the Pharmaceutical Network and generated by an AI algorithm. Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.